I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.
I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.
At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.
My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.
Conditions and Treatments
Show More Conditions
- Associate Professor, Department of Medicine
- Director, Bellevue Cancer Center
- Section Chief, Hematology and Medical Oncology, Bellevue Hospital
- American Board of Internal Medicine (Hematology), 2007
- American Board of Internal Medicine (Medical Oncology), 2006
- American Board of Internal Medicine - Internal Medicine, 2003
Education and Training
- Fellowship, NYU Medical Center, Hematology/Oncology, 2006
- Fellowship, NYU Medical Center, Hematology/Oncology, 2004
- MD from Albert Einstein College of Med, 2000
Clinical Trials and Research Studies
A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
World journal of gastrointestinal oncology. 2018 May 15; 10(5):108-114
Breast cancer research & treatment. 2018 Feb ; 168(1):57-67
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC) [Meeting Abstract]
Journal of clinical oncology. 2018 February; Conference:(2018):